Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Taltz Autoinjector
| Field | Information |
|---|---|
| Medication Name | Taltz Autoinjector |
| Generic Name | Ixekizumab |
| Purpose | Treatment of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis |
| Mechanism of Action | Binds to interleukin-17A (IL-17A), a protein that causes inflammation, and prevents it from binding to its receptor. |
| Dosage Forms | Subcutaneous injection (autoinjector, prefilled syringe) |
| Available Strengths | 80 mg/mL |
| Dosage Frequency | Varies by condition; typically every 2-4 weeks after an initial loading dose |
| Common Side Effects | Injection site reactions (redness, pain, swelling), upper respiratory infections, nausea, fungal infections |
| Serious Side Effects | Serious infections (e.g., tuberculosis), inflammatory bowel disease (new or worsening), allergic reactions |
| Drug Interactions | Live vaccines, immunosuppressants (use with caution) |
| Important Notes | Monitor for signs of infection; avoid live vaccines during treatment. Inform your doctor if you have a history of tuberculosis or inflammatory bowel disease. |
| Storage | Store in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze. Keep in the original carton to protect from light. |
| Missed Dose | Inject as soon as you remember. Then, continue with your next injection as originally scheduled. |
| Alternatives | Cosentyx (secukinumab), Humira (adalimumab), Stelara (ustekinumab), Enbrel (etanercept) |
Taltz Autoinjector Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Cosentyx (secukinumab) | IL-17A inhibitor | Similar mechanism of action; also used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. |
| Humira (adalimumab) | TNF-alpha inhibitor | Different mechanism; targets TNF-alpha, another inflammatory protein; used for various autoimmune conditions. |
| Stelara (ustekinumab) | IL-12/IL-23 inhibitor | Targets different inflammatory proteins; used for psoriasis and psoriatic arthritis. |
| Enbrel (etanercept) | TNF-alpha inhibitor | Similar to Humira in mechanism; used for various autoimmune conditions. |
Taltz Autoinjector Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Injection site reactions (redness, pain, swelling) | Serious infections (e.g., tuberculosis) |
| Upper respiratory infections | Inflammatory bowel disease (new or worsening) |
| Nausea | Allergic reactions (rash, itching, swelling, difficulty breathing) |
| Fungal infections (e.g., athlete’s foot) | Severe neutropenia (low white blood cell count) |
| Conjunctivitis | Hepatitis |
Taltz Autoinjector Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Plaque Psoriasis | 160 mg (two 80 mg injections) at Week 0, followed by 80 mg every 2 weeks for 12 weeks | 80 mg every 4 weeks | Subcutaneous injection. Rotate injection sites. |
| Psoriatic Arthritis | 160 mg (two 80 mg injections) at Week 0, followed by 80 mg every 2 weeks for 12 weeks | 80 mg every 4 weeks | May be used alone or in combination with other DMARDs. Subcutaneous injection. Rotate injection sites. |
| Ankylosing Spondylitis | 160 mg (two 80 mg injections) at Week 0, followed by 80 mg every 2 weeks for 12 weeks | 80 mg every 4 weeks | Subcutaneous injection. Rotate injection sites. |
| Non-radiographic Axial Spondyloarthritis | 160 mg (two 80 mg injections) at Week 0, followed by 80 mg every 2 weeks for 12 weeks | 80 mg every 4 weeks | Subcutaneous injection. Rotate injection sites. |
